Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hERV-based cancer vaccine
- Development stage
- Preclinical
- Lead developer
- Sementis
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The hERV-based cancer vaccine is a therapeutic vaccine candidate developed by Sementis using its proprietary Sementis Copenhagen Vector (SCV) platform. The vaccine is designed to target human endogenous retroviruses (hERVs), which are ancient viral sequences integrated into the human genome that are typically silenced in healthy cells but become reactivated and expressed as antigens in various malignancies. By utilizing the SCV platform—a multi-antigen, non-replicating viral vector derived from the vaccinia virus—the vaccine aims to stimulate a robust immune response against hERV-expressing tumor cells. The program is currently in the IND-enabling phase for the treatment of various cancers.
- Other names
- Sementis hERV cancer vaccineSCV-hERV vaccine
02
Targets
Human endogenous retrovirus envelope-derived peptide–major histocompatibility complexHuman endogenous retrovirus envelope protein (HERV Env)PRR (Pattern recognition receptors)
Beyond the preview
Go deeper on hERV-based cancer vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on hERV-based cancer vaccine.